5^th October 2026: Cryoviva Life Sciences has been recognised with the Kalam Medal of Excellence in Genomic Innovation at The Next Gene – India’s BioScience Summit 2026, for the continuous effort of innovation from the company that contributes significantly to the development of the biosciences and genomics landscape. This is in light of how genomics continues to be at the heart of the conversation of preventive healthcare, personalized medicine, diagnostics, and biomedical research. This opens up a world of possibilities for organizations that operate within the intersection of science, technology and healthcare. It is therefore a momentous occasion for Cryoviva Life Sciences, in terms of its journey of innovation through scientific advancements and research.

Commenting on the recognition, Mr. Vikas Sharma, Chief Operating Officer, Cryoviva Life Sciences, said, “Receiving the Kalam Medal of Excellence in Genomic Innovation is a proud moment for the entire Cryoviva Life Sciences team. This recognition reinforces our belief that meaningful innovation is driven by a combination of scientific excellence, continuous learning and a clear commitment to creating long-term value for the healthcare ecosystem. Genomics is opening new possibilities in the way we understand health, disease and personalised care, and we are committed to contributing responsibly to this rapidly evolving field. I dedicate this recognition to our team whose passion, expertise and relentless pursuit of innovation continue to move us forward.”

The honour at The Next Gene 2026 further strengthens Cryoviva Life Sciences’ focus on advancing scientific possibilities and participating actively in conversations shaping the future of biosciences.

Going forward, the company aims to continue investing in knowledge, collaboration and innovation while working towards solutions that can contribute to the next phase of genomic science and healthcare advancement.

About Cryoviva Life Sciences

Founded in 2006, Cryoviva Life Sciences offers end-to-end solutions across umbilical cord blood and tissue banking, cellular therapies, and next-generation stem cell applications, with a focus on turning cutting-edge research into real-world medical impact. With a state-of-the-art processing

and storage facility, based on globally aligned protocols and advanced cryopreservation technologies, Cryoviva has become one of the most trusted names in India’s stem cell banking space. Today, over 350,000 families have placed their trust in Cryoviva to safeguard their child’s stem cells for future healthcare needs. Beyond India, Cryoviva has established a strong international presence, operating across Vietnam, Thailand, Singapore, making it the only Indian cord blood bank with such a sustained global footprint. This global reach reinforces Cryoviva’s mission to make safe, reliable, and life-saving stem cell technologies accessible across geographies.